Acitor Biotech’s Stroke Treatment Gets PRIME Status from EMA

Image from Freestock

Stroke is a leading killer worldwide that has few effective treatment options. Acitor Biotech’s experimental stroke treatment glenzocimab, a monoclonal antibody targetting clot formation, has just recieved Priority Medicines (PRIME) status with the European Medicines Agency. This designation helps bolster support for treatments that meet a currently unmet or underserved medical need.

According to Acitor, “Glenzocimab is currently being evaluated in the Phase 2/3 registration ACTISAVE study in stroke patients. This study started in Q3 2021, with the inclusion of the first patient in Europe. In parallel, ACTICOR had obtained an IND for this study from the U.S. Food and Drug Administration (FDA) in November 2021. To date, 87 patients have already been enrolled in Europe.”

To read more, click here.

(Source: Business Wire, July 21st, 2022)